FDA Reviews Oral GLP-1 Receptor Agonist for Chronic Weight Management Under Accelerated Program
The US Food and Drug Administration accepted a New Drug Application for orforglipron in late 2025. The investigational therapy targets chronic weight management in adults with obesity or overweight accompanied by weight-related comorbidities. Orforglipron is a once-daily oral small molecule glucagon-like peptide-1 receptor agonist developed by Eli Lilly and Company. The agency extended its review deadline to April 10 after initially targeting March for a decision.
The application is under evaluation through the FDA Commissioner’s National Priority Voucher Pilot Program. This initiative accelerates review of therapies addressing significant US public health priorities through intensive senior level multidisciplinary assessment. The program maintains standard safety, efficacy, and quality requirements while substantially shortening review timelines. Consequently, it differs from traditional Priority Review, which reduces review duration based on disease severity and unmet medical need.
Orforglipron represents a structural departure from peptide based GLP-1 receptor agonists that currently dominate obesity treatment. Most existing GLP-1 therapies require subcutaneous injection. Oral semaglutide remains the only approved oral formulation for obesity treatment at present. Nevertheless, oral semaglutide relies on a peptide structure requiring strict fasting and water only dosing conditions to enable gastrointestinal absorption.
In contrast, orforglipron is a non-peptide small molecule designed for once daily administration without fasting restrictions. The agent activates GLP-1 receptors to enhance glucose dependent insulin secretion, suppress appetite, and delay gastric emptying. These mechanisms align with established incretin pharmacology. Moreover, the chemical structure and delivery profile differentiate orforglipron from existing peptide formulations, potentially improving convenience, scalability, and long term adherence.
The New Drug Application draws support from three Phase 3 clinical trials within the ATTAIN program. ATTAIN-1 enrolled 3,127 adults with obesity but without diabetes. Participants receiving orforglipron at 6 mg, 12 mg, and 36 mg achieved mean body weight reductions of 7.5%, 8.4%, and 11.2% respectively at week 72 compared with 2.1% for placebo. Furthermore, 54.6% of patients receiving the 36 mg dose achieved at least 10% weight loss versus 12.9% with placebo. The trial also demonstrated improvements in waist circumference, blood pressure, lipid parameters, and glycemic measures.
ATTAIN-2 evaluated 1,613 adults with obesity or overweight and coexisting type 2 diabetes. Mean body weight reductions at week 72 reached 5.1%, 7.0%, and 9.6% with orforglipron 6 mg, 12 mg, and 36 mg respectively compared with 2.5% for placebo. Building on this, 45.6% of patients receiving 36 mg achieved at least 10% weight loss versus 9.0% with placebo. The trial additionally showed hemoglobin A1C reductions up to 1.66% alongside improvements in waist circumference, blood pressure, and lipid profiles.
ATTAIN-MAINTAIN assessed weight loss maintenance in adults who completed 72 weeks of injectable semaglutide or tirzepatide therapy. Participants switching to orforglipron maintained nearly all previously achieved weight reduction over 52 weeks. Notably, average weight regain measured approximately 0.9 kg following semaglutide and roughly 5 kg after tirzepatide when orforglipron was combined with diet and physical activity.
Gastrointestinal adverse events constituted the most common safety concerns across all trials. These events were generally mild to moderate in severity and occurred primarily during dose escalation. The safety profile remained consistent with the established GLP-1 receptor agonist class.
Eli Lilly plans to submit an additional application for orforglipron in type 2 diabetes later this year. This submission will draw on findings from the Phase 3 ACHIEVE clinical trial program, which evaluates glycemic control and cardiometabolic outcomes in adults with type 2 diabetes.
